Partner Brent Babcock, Chair of the firm’s USPTO Trials & Post-Grant Proceedings group, was quoted in “Some Consensus in the CRISPR Patent Case,” an article published in MedCity News. The article discuses four companies founded in the CRISPR space that announced last Friday, December 16, that they had formed an IP alliance.
Subscribe for News and Updates